These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21727212)

  • 1. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
    Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
    Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
    Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
    Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
    Ammoun S; Flaiz C; Ristic N; Schuldt J; Hanemann CO
    Cancer Res; 2008 Jul; 68(13):5236-45. PubMed ID: 18593924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
    Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
    Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
    Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
    Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244.
    Ammoun S; Ristic N; Matthies C; Hilton DA; Hanemann CO
    Neurobiol Dis; 2010 Jan; 37(1):141-6. PubMed ID: 19804833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
    Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
    Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
    Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
    Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
    Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
    Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
    Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.
    Ammoun S; Hanemann CO
    Nat Rev Neurol; 2011 Jun; 7(7):392-9. PubMed ID: 21647202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation.
    Fraenzer JT; Pan H; Minimo L; Smith GM; Knauer D; Hung G
    Int J Oncol; 2003 Dec; 23(6):1493-500. PubMed ID: 14612918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalytically inactive SHIP2 inhibits proliferation by attenuating PDGF signaling in 3T3-L1 preadipocytes.
    Artemenko Y; Gagnon A; Sorisky A
    J Cell Physiol; 2009 Jan; 218(1):228-36. PubMed ID: 18814181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
    Abouantoun TJ; MacDonald TJ
    Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.
    Terabe F; Kitano M; Kawai M; Kuwahara Y; Hirano T; Arimitsu J; Hagihara K; Shima Y; Narazaki M; Tanaka T; Kawase I; Sano H; Ogata A
    Mod Rheumatol; 2009; 19(5):522-9. PubMed ID: 19568828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.
    Patwardhan PP; Surriga O; Beckman MJ; de Stanchina E; Dematteo RP; Tap WD; Schwartz GK
    Clin Cancer Res; 2014 Jun; 20(12):3146-58. PubMed ID: 24718867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
    McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
    Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
    Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.